Abstract
Colorectal cancer (CRC) is one prominent example for how chemotherapy has been changing by moving from the use of general cytotoxic agents to more tumour-specific drugs. For example, antibody-based drugs neutralize a growth factor receptor protein on the surface of tumour cells. The development of such new therapeutic opportunities requires a more thorough and systematic subclassification of CRC because tumour cells can exploit several alternative genetic pathways for their survival. This chapter gives an overview on CRC subtypes as an introduction to the following book chapters that will describe aspects of specific subtypes, and how these may lead to the development of novel pathway-specific drugs for a more precise therapeutic intervention.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F (2017) Global patterns and trends in colorectal cancer incidence and mortality. Gut 66:683–691. https://doi.org/10.1136/gutjnl-2015-310912
Bardelli A, Siena S (2010) Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28:1254–1261. https://doi.org/10.1200/JCO.2009.24.6116
Beach R, Chan AO-O, Wu T-T, White JA, Morris JS, Lunagomez S, Broaddus RR, Issa J-PJ, Hamilton SR, Rashid A (2005) BRAF mutations in aberrant crypt foci and hyperplastic polyposis. Am J Pathol 166:1069–1075. https://doi.org/10.1016/S0002-9440(10)62327-9
Bettington M, Walker N, Clouston A, Brown I, Leggett B, Whitehall V (2013) The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology 62:367–386. https://doi.org/10.1111/his.12055
Boparai KS, Dekker E, Polak MM, Musler AR, van Eeden S, van Noesel CJM (2011) A serrated colorectal cancer pathway predominates over the classic WNT pathway in patients with hyperplastic polyposis syndrome. Am J Pathol 178:2700–2707. https://doi.org/10.1016/j.ajpath.2011.02.023
Brenner H, Kloor M, Pox CP (2014) Colorectal cancer. Lancet 383:1490–1502. https://doi.org/10.1016/S0140-6736(13)61649-9
Budinska E, Popovici V, Tejpar S, D’Ario G, Lapique N, Sikora KO, Di Narzo AF, Yan P, Hodgson JG, Weinrich S, Bosman F, Roth A, Delorenzi M (2013) Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer: gene expression heterogeneity in colorectal cancer. J Pathol 231:63–76. https://doi.org/10.1002/path.4212
Calon A, Lonardo E, Berenguer-Llergo A, Espinet E, Hernando-Momblona X, Iglesias M, Sevillano M, Palomo-Ponce S, Tauriello DVF, Byrom D, Cortina C, Morral C, Barceló C, Tosi S, Riera A, Attolini CS-O, Rossell D, Sancho E, Batlle E (2015) Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet 47:320–329. https://doi.org/10.1038/ng.3225
Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330–337. https://doi.org/10.1038/nature11252
Carr NJ, Mahajan H, Tan KL, Hawkins NJ, Ward RL (2009) Serrated and non-serrated polyps of the colorectum: their prevalence in an unselected case series and correlation of BRAF mutation analysis with the diagnosis of sessile serrated adenoma. J Clin Pathol 62:516–518. https://doi.org/10.1136/jcp.2008.061960
Day FL, Jorissen RN, Lipton L, Mouradov D, Sakthianandeswaren A, Christie M, Li S, Tsui C, Tie J, Desai J, Xu Z-Z, Molloy P, Whitehall V, Leggett BA, Jones IT, McLaughlin S, Ward RL, Hawkins NJ, Ruszkiewicz AR, Moore J, Busam D, Zhao Q, Strausberg RL, Gibbs P, Sieber OM (2013) PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. Clin Cancer Res 19:3285–3296. https://doi.org/10.1158/1078-0432.CCR-12-3614
De Sousa E, Melo F, Wang X, Jansen M, Fessler E, Trinh A, de Rooij LPMH, de Jong JH, de Boer OJ, van Leersum R, Bijlsma MF, Rodermond H, van der Heijden M, van Noesel CJM, Tuynman JB, Dekker E, Markowetz F, Medema JP, Vermeulen L (2013) Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 19:614–618. https://doi.org/10.1038/nm.3174
Fearon ER (2011) Molecular genetics of colorectal cancer. Annu Rev Pathol Mech Dis 6:479–507. https://doi.org/10.1146/annurev-pathol-011110-130235
Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759–767. https://doi.org/10.1016/0092-8674(90)90186-I
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386. https://doi.org/10.1002/ijc.29210
Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E, Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S (2015) The consensus molecular subtypes of colorectal cancer. Nat Med 21:1350–1356. https://doi.org/10.1038/nm.3967
Isella C, Terrasi A, Bellomo SE, Petti C, Galatola G, Muratore A, Mellano A, Senetta R, Cassenti A, Sonetto C, Inghirami G, Trusolino L, Fekete Z, De Ridder M, Cassoni P, Storme G, Bertotti A, Medico E (2015) Stromal contribution to the colorectal cancer transcriptome. Nat Genet 47:312–319. https://doi.org/10.1038/ng.3224
Isella C, Brundu F, Bellomo SE, Galimi F, Zanella E, Porporato R, Petti C, Fiori A, Orzan F, Senetta R, Boccaccio C, Ficarra E, Marchionni L, Trusolino L, Medico E, Bertotti A (2017) Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer. Nat Commun 8:15107. https://doi.org/10.1038/ncomms15107
Jass JR (2007) Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50:113–130. https://doi.org/10.1111/j.1365-2559.2006.02549.x
Kim K-M, Lee EJ, Ha S, Kang SY, Jang K-T, Park CK, Kim JY, Kim YH, Chang DK, Odze RD (2011) Molecular features of colorectal hyperplastic polyps and sessile serrated adenoma/polyps from Korea. Am J Surg Pathol 35:1274–1286. https://doi.org/10.1097/PAS.0b013e318224cd2e
Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L, Etienne-Grimaldi M-C, Schiappa R, Guenot D, Ayadi M, Kirzin S, Chazal M, Fléjou J-F, Benchimol D, Berger A, Lagarde A, Pencreach E, Piard F, Elias D, Parc Y, Olschwang S, Milano G, Laurent-Puig P, Boige V (2013) Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med 10:e1001453. https://doi.org/10.1371/journal.pmed.1001453
Matos P, Gonçalves V, Jordan P (2016) Targeting the serrated pathway of colorectal cancer with mutation in BRAF. Biochim Biophys Acta BBA – Rev Cancer 1866:51–63. https://doi.org/10.1016/j.bbcan.2016.06.003
Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A (2014) Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov 4:1269–1280. https://doi.org/10.1158/2159-8290.CD-14-0462
Obaid N, Bedard K, Huang W-Y (2017) Strategies for overcoming resistance in tumours harboring BRAF mutations. Int J Mol Sci 18:585. https://doi.org/10.3390/ijms18030585
Perez Villamil B, Romera Lopez A, Hernandez Prieto S, Lopez Campos G, Calles A, Lopez Asenjo JA, Sanz Ortega J, Fernandez Perez C, Sastre J, Alfonso R, Caldes T, Martin Sanchez F, Diaz Rubio E (2012) Colon cancer molecular subtypes identified by expression profiling and associatedto stroma, mucinous type and different clinical behavior. BMC Cancer 12:260. https://doi.org/10.1186/1471-2407-12-260
Phipps AI, Limburg PJ, Baron JA, Burnett-Hartman AN, Weisenberger DJ, Laird PW, Sinicrope FA, Rosty C, Buchanan DD, Potter JD, Newcomb PA (2015) Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology 148:77–87.e2. https://doi.org/10.1053/j.gastro.2014.09.038
Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V, Snel MH, Chresta CM, Rosenberg R, Nitsche U, Macarulla T, Capella G, Salazar R, Orphanides G, Wessels LF, Bernards R, Simon IM (2014) Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition: molecular subtypes in colorectal cancer. Int J Cancer 134:552–562. https://doi.org/10.1002/ijc.28387
Rosenberg DW, Yang S, Pleau DC, Greenspan EJ, Stevens RG, Rajan TV, Heinen CD, Levine J, Zhou Y, O’Brien MJ (2007) Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans. Cancer Res 67:3551–3554. https://doi.org/10.1158/0008-5472.CAN-07-0343
Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LCG, Lannon WA, Grotzinger C, Del Rio M, Lhermitte B, Olshen AB, Wiedenmann B, Cantley LC, Gray JW, Hanahan D (2013) A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 19:619–625. https://doi.org/10.1038/nm.3175
Sandmeier D, Benhattar J, Martin P, Bouzourene H (2009) Serrated polyps of the large intestine: a molecular study comparing sessile serrated adenomas and hyperplastic polyps. Histopathology 55:206–213. https://doi.org/10.1111/j.1365-2559.2009.03356.x
Schlicker A, Beran G, Chresta CM, McWalter G, Pritchard A, Weston S, Runswick S, Davenport S, Heathcote K, Castro DA, Orphanides G, French T, Wessels LF (2012) Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med Genet 5:66. https://doi.org/10.1186/1755-8794-5-66
Snover DC, Jass JR, Fenoglio-Preiser C, Batts KP (2005) Serrated polyps of the large intestine: a morphologic and molecular review of an evolving concept. Am J Clin Pathol 124:380–391. https://doi.org/10.1309/V2EP-TPLJ-RB3F-GHJL
Velho S, Moutinho C, Cirnes L, Albuquerque C, Hamelin R, Schmitt F, Carneiro F, Oliveira C, Seruca R (2008) BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? BMC Cancer 8:255. https://doi.org/10.1186/1471-2407-8-255
Whitehall VLJ, Rickman C, Bond CE, Ramsnes I, Greco SA, Umapathy A, McKeone D, Faleiro RJ, Buttenshaw RL, Worthley DL, Nayler S, Zhao ZZ, Montgomery GW, Mallitt K-A, Jass JR, Matsubara N, Notohara K, Ishii T, Leggett BA (2012) Oncogenic PIK3CA mutations in colorectal cancers and polyps. Int J Cancer 131:813–820. https://doi.org/10.1002/ijc.26440
Yang S, Farraye FA, Mack C, Posnik O, O’Brien MJ (2004) BRAF and KRAS mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am J Surg Pathol 28:1452–1459. https://doi.org/10.1097/01.pas.0000141404.56839.6a
Zhao L, Vogt PK (2010) Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle Georget Tex 9:596–600. https://doi.org/10.4161/cc.9.3.10599
Zhao B, Wang L, Qiu H, Zhang M, Sun L, Peng P, Yu Q, Yuan X (2017) Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. Oncotarget 8:3980–4000. https://doi.org/10.18632/oncotarget.14012
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Jordan, P. (2018). Colorectal Cancer Subtypes – The Current Portrait. In: Jordan, P. (eds) Targeted Therapy of Colorectal Cancer Subtypes. Advances in Experimental Medicine and Biology, vol 1110. Springer, Cham. https://doi.org/10.1007/978-3-030-02771-1_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-02771-1_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-02770-4
Online ISBN: 978-3-030-02771-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)